A Pilot Presurgical Study Evaluating Anti-Pd-L1 Durvalumab (Durva) Plus Anti-Ctla-4 Tremelimumab (Treme) In Patients (Pts) With High-Risk Muscle-Invasive Bladder Carcinoma (Mibc) Who Are Ineligible For Cisplatin-Based Neoadjuvant Chemotherapy (Nac).
JOURNAL OF CLINICAL ONCOLOGY（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要